Stearns Financial Services Group decreased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 6.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,447 shares of the biopharmaceutical company’s stock after selling 710 shares during the period. Stearns Financial Services Group’s holdings in Bristol-Myers Squibb were worth $582,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp boosted its position in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after acquiring an additional 178,436 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Bristol-Myers Squibb by 4.3% during the 1st quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after acquiring an additional 335,795 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Bristol-Myers Squibb by 27.2% during the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares in the last quarter. Institutional investors and hedge funds own 68.84% of the company’s stock.

WARNING: “Stearns Financial Services Group Has $582,000 Position in Bristol-Myers Squibb Company (BMY)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://theolympiareport.com/2017/10/21/stearns-financial-services-group-has-582000-position-in-bristol-myers-squibb-company-bmy.html.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) opened at 64.42 on Friday. The company has a market cap of $105.64 billion, a P/E ratio of 23.53 and a beta of 1.19. The stock’s 50 day moving average is $63.37 and its 200 day moving average is $57.29. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.69 EPS. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.99 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.42%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.

BMY has been the topic of several analyst reports. UBS AG reiterated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a research report on Monday, October 9th. BMO Capital Markets restated a “sell” rating and issued a $49.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, September 4th. BidaskClub upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $66.00 target price (up previously from $63.00) on shares of Bristol-Myers Squibb in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $63.79.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.